{"text": ["AbbVie's", "Skyrizi", "drug", "to", "treat", "psoriasis", "wins", "U.S.", "approval"], "created_at": "2019-04-23 23:31:10"}
{"text": ["AbbVie", "stock", "ticks", "higher", "on", "FDA", "approval", "of", "psoriasis", "treatment"], "created_at": "2019-04-23 22:37:00"}
{"text": ["AbbVie", "Expands", "Immunology", "Portfolio", "in", "the", "U.S.", "with", "FDA", "Approval", "of", "SKYRIZI\u2122", "(risankizumab-rzaa)", "for", "Moderate", "to", "Severe", "Plaque", "Psoriasis"], "created_at": "2019-04-23 22:19:00"}
{"text": ["You", "can", "find", "plenty", "of", "solid", "stock", "bargains", "in", "this", "year\u2019s", "worst-performing", "sector,", "analyst", "says"], "created_at": "2019-04-23 18:44:00"}
{"text": ["Analysts", "see", "plenty", "of", "attractive", "bargains", "in", "this", "year\u2019s", "worst-performing", "stock", "sector"], "created_at": "2019-04-23 17:33:00"}
